ZEB2-mediated upregulation of Il7r expression and activation of the JAK/STAT pathway represents a possible therapeutic target for this aggressive and chemoresistant subtype of human T-ALL. The gene discussed is IL7R; the disease is acute lymphoblastic leukemia.